Faculty and Staff Publications
Language
English
Publication Date
1-1-2025
Journal
ACG Case Reports
DOI
10.14309/crj.0000000000001575
PMID
39734393
PMCID
PMC11671078
PubMedCentral® Posted Date
12-27-2024
PubMedCentral® Full Text Version
Post-print
Abstract
Long-acting injectable formulation of cabotegravir/rilpivirine (CAB/RPV) is a promising novel maintenance therapy for HIV infection. However, coinfection with active hepatitis B virus (HBV) infection is a contraindication to initiating this therapy. Despite guidelines, patients with HBV immunity can still contract acute HBV infection. We report a case of a 30-year-old man with HIV who transitioned from antiretroviral therapy to CAB/RPV and had confirmed HBV immunity. The patient, though asymptomatic, showed significantly elevated liver function tests (LFTs) before his monthly CAB/RPV injection. He was hospitalized and diagnosed with acute HBV infection. His LFTs improved, and he was taken off CAB/RPV and returned to antiretroviral therapy for the treatment of HIV and HBV. During subsequent follow-ups as an outpatient, the patient's LFTs normalized, and his HBV viral load significantly decreased. This case highlights the potential need for routine HBV testing in patients on CAB/RPV therapy.
Keywords
hepatitis, hepatitis B, HIV, cabotegravir, rilpivirine
Published Open-Access
yes
Recommended Citation
Boateng, William K B; Carlin, Neil; Spira, Etan; et al., "Acute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/Rilpivirine" (2025). Faculty and Staff Publications. 2.
https://digitalcommons.library.tmc.edu/ethics_pub/2